<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35546539</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2150-7511</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>mBio</Title>
          <ISOAbbreviation>mBio</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Rapid Capsular Antigen Immunoassay for Diagnosis of Inhalational Anthrax: Preclinical Studies and Evaluation in a Nonhuman Primate Model.</ArticleTitle>
        <Pagination>
          <StartPage>e0093122</StartPage>
          <MedlinePgn>e0093122</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1128/mbio.00931-22</ELocationID>
        <Abstract>
          <AbstractText>Inhalational anthrax is a fatal infectious disease. Rapid and effective treatment is critically dependent on early and accurate diagnosis. Blood culture followed by identification and confirmation may take days to provide clinically relevant information. In contrast, immunoassay for a shed antigen, the capsular polypeptide gamma-d-polyglutamate (γDPGA), can provide rapid results at the point of care. In this study, a lateral flow immunoassay for γDPGA was evaluated in a robust nonhuman primate model of inhalational anthrax. The results showed that the time to a positive result with the rapid test using either serum or blood as a clinical specimen was similar to the time after infection when a blood culture became positive. <i>In vitro</i> testing showed that the test was equally sensitive with cultures of the three major clades of Bacillus anthracis. Cultures from other <i>Bacillus</i> spp. that are known to produce γDPGA also produced positive results. The test was negative with human sera from 200 normal subjects and 45 subjects with culture-confirmed nonanthrax bacterial or fungal sepsis. Taken together, the results showed that immunoassay for γDPGA is an effective surrogate for blood culture in a relevant cynomolgus monkey model of inhalational anthrax. The test would be a valuable aid in early diagnosis of anthrax, which is critical for rapid intervention and a positive outcome. Use of the test could facilitate triage of patients with signs and symptoms of anthrax in a mass-exposure incident and in low-resource settings where laboratory resources are not readily available. <b>IMPORTANCE</b> Patient outcome in anthrax is critically dependent on early diagnosis followed by effective treatment. We describe a rapid lateral flow immunoassay that detects capsular antigen of Bacillus anthracis that is shed into blood during infection. The test was evaluated in a robust cynomolgus monkey model of inhalational anthrax. Rapid detection of capsular antigen is an effective surrogate for the time-consuming and laboratory-intensive diagnosis by blood culture, direct fluorescent antibody staining, or other molecular testing. The test can be performed at the point of patient contact, is rapid and inexpensive, and can be used by individuals with minimal training.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Gates-Hollingsworth</LastName>
            <ForeName>Marcellene A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kolton</LastName>
            <ForeName>Cari B</ForeName>
            <Initials>CB</Initials>
            <AffiliationInfo>
              <Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffmaster</LastName>
            <ForeName>Alex R</ForeName>
            <Initials>AR</Initials>
            <AffiliationInfo>
              <Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meister</LastName>
            <ForeName>Gabriel T</ForeName>
            <Initials>GT</Initials>
            <AffiliationInfo>
              <Affiliation>Battellegrid.27873.39 Biomedical Research Center, Columbus, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moore</LastName>
            <ForeName>Addie E</ForeName>
            <Initials>AE</Initials>
            <AffiliationInfo>
              <Affiliation>Battellegrid.27873.39 Biomedical Research Center, Columbus, Ohio, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Green</LastName>
            <ForeName>Heather R</ForeName>
            <Initials>HR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pogoda</LastName>
            <ForeName>Janice M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Cipher Biostatistics &amp; Reporting, Reno, Nevada, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pillai</LastName>
            <ForeName>Segaran P</ForeName>
            <Initials>SP</Initials>
            <AffiliationInfo>
              <Affiliation>Office of the Commissioner, Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kozel</LastName>
            <ForeName>Thomas R</ForeName>
            <Initials>TR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology and Immunology, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI059348</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI093365</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>U01 AI061200</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>mBio</MedlineTA>
        <NlmUniqueID>101519231</NlmUniqueID>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Bacillus anthracis</Keyword>
        <Keyword MajorTopicYN="N">anthrax</Keyword>
        <Keyword MajorTopicYN="N">capsule</Keyword>
        <Keyword MajorTopicYN="N">diagnosis</Keyword>
        <Keyword MajorTopicYN="N">immunoassay</Keyword>
        <Keyword MajorTopicYN="N">immunoassays</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>1</Hour>
          <Minute>53</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35546539</ArticleId>
        <ArticleId IdType="doi">10.1128/mbio.00931-22</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
